Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 8Flow Cytometry 6Methylprednisolone 5Melphalan 5Therapeutics 4Psychiatric Rehabilitation 4Busulfan 4Antilymphocyte Serum 4Radiotherapy 3Polymerase Chain Reaction 3Immunologic Techniques 3Filgrastim 3Caspofungin 3Amplified Fragment Length Polymorphism Analysis 3Alemtuzumab 3venetoclax 2thymoglobulin 2liposomal amphotericin B 2fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Voriconazole 2Thiotepa 2Thalidomide 2Peripheral Blood Stem Cell Transplantation 2Ondansetron 2Nivolumab 2Itraconazole 2Ipilimumab 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Fenofibrate × Other hematologic neoplasm × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡